SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:
- 8th Annual Needham Life Sciences Conference on Wednesday, June 10, 2009 at 9:00 a.m. Eastern Time at the New York Palace Hotel in New York City.
- Jefferies' 3rd Annual Healthcare Conference on Thursday, June 18, 2009 at 1:30 p.m. Eastern Time at the Mandarin Oriental Hotel in New York City.
- Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 3:00 p.m. British Summer Time (8:00 a.m. Eastern Time) at the ANdAZ Hotel in London.
Live audio webcasts of these presentations will be accessible on the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
Porter Novelli Life Sciences
Jason I. Spark, Vice President
Related biology technology :1
|SOURCE Optimer Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI2
. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results3
. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference4
. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis5
. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting6
. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study7
. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer8
. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial9
. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system10
. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 200911
. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009